Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix

NEW YORK, September 3, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.

--
SL Green Realty Corp. Research Reports
On August 29, 2014, the stock of SL Green Realty Corp. (SL Green) gained 0.12% to end the trading session at $109.35. During the session, shares in SL Green opened at $109.70, and fluctuated in the range of $109.02 - $109.88, with a total of 1.30 million shares changing hands. Over the last one month, the Company's stock has remained largely unchanged, while the Dow Jones Industrial Average increased 1.29% during that period. The full research reports on SL Green are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/SLG/report.pdf

--
The Allstate Corporation Research Reports
On August 28, 2014, The Allstate Corporation (Allstate) announced that Thomas J. Wilson, the Company's Chairman, President and CEO, will present at the Barclays Global Financial Services Conference at 8:15 a.m. ET on September 10, 2014. The conference will be held at the New York Hilton Midtown, New York. Allstate added that a webcast of the presentation, along with its replay, will be posted on the Investor Relations and Executive Speeches sections of the Company's website. The full research reports on Allstate are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/ALL/report.pdf

--
HCA Research Reports
On August 27, 2014, HCA Holdings, Inc. (HCA) reported that it will present at the Baird Health Care Conference to be held at The New York Palace Hotel in New York on September 4, 2014 at 2:35 p.m. (EDT). Furthermore, the Company will also present at the Morgan Stanley Global Healthcare Conference on September 9, 2014 at the Grand Hyatt New York in New York, at 2:05 p.m. (EDT). An audio webcast of the events can be accessed at the Company's website under Investor Relations section. The full research reports on HCA Holdings are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/HCA/report.pdf

--
Alexion Pharmaceuticals, Inc. Research Reports
On August 25, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial for evaluating the efficacy and safety of eculizumab (Soliris®) for preventing delayed graft function (DGF). The trial involves adult patients who are at increased risk of DGF and have undergone kidney transplantation. "Delayed graft function is a serious and significant complication to successful kidney transplantation, which can be life-threatening due to the risk of losing the transplanted organ. Since complement activation plays a critical role in the development of DGF, a terminal complement inhibitor like eculizumab may have the potential to prevent this devastating complication. In addition, as donor organs are in short supply, reducing the risk of DGF may allow more deceased-donor organs to be successfully transplanted, which could potentially shorten the waiting time to receive a transplant," said Martin Mackay, Ph.D., Executive Vice President and Global head of R&D at Alexion. The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/ALXN/report.pdf

--
Salix Pharmaceuticals Ltd. Research Reports
On August 21, 2014, Bloomberg reported that Salix Pharmaceuticals Ltd (Salix), which is in the process of merger with a unit of Swiss-listed Cosmo Pharmaceuticals SpA, is currently not in active talks with Allergan Inc. (Allergan) for a potential takeover deal. According to the report, Allergan had approached Salix about buying the drugmaker in order to avert a hostile takeover from Valeant Pharmaceuticals International Inc. However, the report added, the talks between Salix and Allergan are dormant now, with the latter continuing to explore other options. The full research reports on Salix are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/SLXP/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED